Your browser is no longer supported. Please, upgrade your browser.
Phathom Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-6.81 Insider Own17.16% Shs Outstand25.92M Perf Week7.82%
Market Cap1.24B Forward P/E- EPS next Y-4.10 Insider Trans-3.42% Shs Float9.60M Perf Month-1.53%
Income-173.40M PEG- EPS next Q-1.03 Inst Own70.40% Short Float8.43% Perf Quarter6.39%
Sales- P/S- EPS this Y84.30% Inst Trans-0.12% Short Ratio6.31 Perf Half Y23.07%
Book/sh6.03 P/B6.49 EPS next Y-16.10% ROA-69.00% Target Price51.33 Perf Year5.10%
Cash/sh7.12 P/C5.50 EPS next 5Y- ROE-88.70% 52W Range22.06 - 64.54 Perf YTD17.85%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-39.14% Beta-
Dividend %- Quick Ratio8.20 Sales past 5Y- Gross Margin- 52W Low78.06% ATR2.33
Employees25 Current Ratio8.20 Sales Q/Q- Oper. Margin- RSI (14)54.31 Volatility4.66% 5.60%
OptionableYes Debt/Eq0.30 EPS Q/Q52.60% Profit Margin- Rel Volume0.60 Prev Close39.15
ShortableYes LT Debt/Eq0.26 Earnings- Payout- Avg Volume128.21K Price39.28
Recom2.30 SMA209.54% SMA50-3.05% SMA2003.59% Volume62,741 Change0.33%
Jun-26-20Downgrade Goldman Neutral → Sell $34
Nov-20-19Initiated Evercore ISI Outperform
Nov-19-19Initiated Needham Buy $40
Nov-19-19Initiated Jefferies Buy $32
Nov-19-19Initiated Goldman Neutral $32
Jan-19-21 08:30AM  
Dec-16-20 06:43PM  
Dec-15-20 04:01PM  
Dec-14-20 08:30AM  
Dec-08-20 09:00AM  
Dec-02-20 11:33PM  
Nov-30-20 04:05PM  
Nov-27-20 08:00AM  
Nov-19-20 04:05PM  
Nov-13-20 04:05PM  
Nov-10-20 04:05PM  
Nov-04-20 04:05PM  
Sep-09-20 08:30AM  
Aug-06-20 08:30AM  
Jul-13-20 08:30AM  
Jun-15-20 08:30AM  
Jun-12-20 10:25PM  
May-28-20 04:30PM  
May-12-20 08:30AM  
Apr-09-20 04:30PM  
Mar-19-20 08:30AM  
Feb-25-20 04:35PM  
Jan-16-20 09:00AM  
Jan-06-20 08:30AM  
Dec-23-19 08:30AM  
Dec-02-19 08:30AM  
Nov-26-19 08:30AM  
Nov-25-19 08:30AM  
Nov-13-19 04:05PM  
Oct-29-19 04:05PM  
Oct-25-19 05:10PM  
Oct-24-19 08:25PM  
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Socks David ADirectorJan 12Sale36.0727,165979,7951,532,945Jan 13 05:07 PM
Socks David ADirectorJan 11Sale34.9212,835448,2431,560,110Jan 13 05:07 PM
Socks David ADirectorDec 17Sale40.7448,2121,964,3761,572,945Dec 18 08:01 PM
Socks David ADirectorDec 16Sale47.5331,4461,494,5191,621,157Dec 18 08:01 PM
Nabulsi AzmiChief Operating OfficerDec 02Sale45.267,302330,513838,200Dec 03 06:01 PM
Nabulsi AzmiChief Operating OfficerDec 01Sale44.207,198318,176845,502Dec 03 06:01 PM
Socks David ADirectorNov 11Sale38.976,877268,0211,652,603Nov 12 04:13 PM
Socks David ADirectorNov 10Sale41.6912,681528,6721,659,480Nov 12 04:13 PM
Socks David ADirectorNov 09Sale42.3310,784456,5061,676,562Nov 12 04:13 PM
Nabulsi AzmiChief Operating OfficerNov 02Sale36.8314,500534,026852,700Nov 03 06:40 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerApr 01Buy24.86117,6002,923,6423,825,008Apr 03 04:30 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMar 31Buy24.5530,600751,2643,707,408Mar 31 05:02 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMar 27Buy24.6030,000738,0003,676,808Mar 31 05:02 PM